Skip to main content
. 2018 May;16(5):748–755.e6. doi: 10.1016/j.cgh.2017.09.012

Table 3.

Details of Reported Serious Adverse Events Throughout Trial Treatment Period (Days 1–15)

SAE description Events, n
New ascites 1
Renal impairment 1
Variceal bleeding (death) 3
Variceal bleeding (death) 1
Pneumonia (death) 1
Death (decompensated cirrhosis) 4
Bronchogenic carcinoma and pleural effusion (death) 1
Total deaths in trial treatment period 8 (10%)

SAE, serious adverse event.